Coherus’ Lucentis Biosimilar Outstrips Biogen Rival One Month After Launch
$100m In Cimerli Revenues Anticipated In 2023, Q Code Submitted
One month after launching its Cimerli ranibizumab biosimilar to Lucentis, Coherus BioSciences’ management explained how it had stolen a march on the earlier introduced Byooviz product launched by Biogen/Samsung Bioepis.
You may also be interested in...
With its own interests in the branded eye-disease space, Regeneron has commented on ranibizumab biosimilar sponsor Biogen’s fortunes during a recent conference.
Discussing the latest developments in the US biosimilars market, AmerisourceBergen’s senior director of biosimilar commercialization, Brian Biehn, talks about what we can expect from competition to Humira in 2023, how the first ophthalmology biosimilars are faring, and potential changes on the horizon at the FDA that could smooth the path to market for biosimilars sponsors.
Biogen expects impending biosimilar launches to stimulate new growth, while unfavorable market conditions have taken their toll on the company.